SynthesisBMJ (Clinical research ed.)2012
The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis.
Synthesis in BMJ (Clinical research ed.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 7 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis.Journal of human hypertension · 2019Pooled it
- Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients.Diabetes & vascular disease research · 2017Pooled it
- Blood pressure lowering efficacy of renin inhibitors for primary hypertension.The Cochrane database of systematic reviews · 2017Pooled it
- Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: a meta-analysis of randomized controlled trials.Drug design, development and therapy · 2015Pooled it
- Active vitamin D treatment for reduction of residual proteinuria: a systematic review.Journal of the American Society of Nephrology : JASN · 2013Pooled it
- Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.BMJ (Clinical research ed.) · 2013Pooled it
- Relationship between five GLUT1 gene single nucleotide polymorphisms and diabetic nephropathy: a systematic review and meta-analysis.Molecular biology reports · 2012Pooled it
- A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Trial
- Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers.Journal of cardiovascular pharmacology and therapeutics · 2017Trial
- Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.Clinical and experimental nephrology · 2013Trial
- Pharmacokinetics, mass balance, and metabolism of [Frontiers in pharmacology · 2026Article
- Emerging therapeutic frontiers in hypertension management.Frontiers in cardiovascular medicine · 2025Review
- RNA Interference as a Therapeutic Approach for Managing Hypertension.Clinical journal of the American Society of Nephrology : CJASN · 2024Article
- Quantitative Proteomics Combined with Network Pharmacology Analysis Unveils the Biological Basis of Schisandrin B in Treating Diabetic Nephropathy.Combinatorial chemistry & high throughput screening · 2024Article
- Blood Levels of Angiotensinogen and Hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA).Journal of the American College of Cardiology · 2023Article
- Efficacy of Direct Renin Inhibitors in Slowing Down the Progression of Diabetic Kidney Disease: A Meta-Analysis.Cureus · 2022Review
- Antihypertensive agents: a long way to safe drug prescribing in children.Pediatric nephrology (Berlin, Germany) · 2020Review
- Evolution of Patiromer Use: a Review.Current cardiology reports · 2020Review
- DEEPScreen: high performance drug-target interaction prediction with convolutional neural networks using 2-D structural compound representations.Chemical science · 2020Article
- Therapeutic Renin Inhibition in Diabetic Nephropathy-A Review of the Physiological Evidence.Frontiers in physiology · 2020Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the safety of using aliskiren combined with agents used to block the renin-angiotensin system.
designSystematic review and meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, the Cochrane Library, and two trial registries, published up to 7 May 2011. STUDY SELECTION: Published and unpublished randomised controlled trials that compared combined treatment using aliskiren and angiotensin converting enzyme inhibitors or angiotensin receptor blockers with monotherapy using these agents for at least four weeks and that provided numerical data on the adverse event outcomes of hyperkalaemia and acute kidney injury. A random effects model was used to calculate pooled risk ratios and 95% confidence intervals for these outcomes.
results10 randomised controlled studies (4814 participants) were included in the analysis. Combination therapy with aliskiren and angiotensin converting enzyme inhibitors or angiotensin receptor blockers significantly increased the risk of hyperkalaemia compared with monotherapy using angiotensin converting enzymes or angiotensin receptor blockers (relative risk 1.58, 95% confidence interval 1.24 to 2.02) or aliskiren alone (1.67, 1.01 to 2.79). The risk of acute kidney injury did not differ significantly between the combined therapy and monotherapy groups (1.14, 0.68 to 1.89).
conclusionUse of aliskerin in combination with angiotensin converting enzyme inhibitors or angiotensin receptor blockers is associated with an increased risk for hyperkalaemia. The combined use of these agents warrants careful monitoring of serum potassium levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.